We report here that a patient with relapsed AML after allogeneic bone marrow transplantation achieved and maintained complete remission (CR) after effective donor leukocyte transfusion (DLT), without the occurrence of GVHD and marrow aplasia, for more than 21 months. This continuous CR maintenance is mainly due to the application of DLT at molecular relapse that was diagnosed by monitoring minimal residual disease (MRD) by the quantitation of WT1 (Wilms tumor gene) expression levels (WT1 assay). The present case demonstrates that early application of DLT at molecular relapse is essential for the improvement of the efficacy of DLT for relapsed AML after BMT.
In patients with relapsed chronic myeloid leukemia (CML) after allogeneic bone marrow transplantation (BMT), donor leukocyte transfusion (DLT) from the original marrow donor exerts strong effects in the eradication of leukemia and induces durable remission. 1, 2 However, the prognosis for acute myeloid leukemia (AML) patients with leukemic relapse after BMT is still grim even with DLT. 1, 3, 4 DLT performed for CML patients with cytogenetic or molecular relapse after BMT was reported to be associated with an increased likelihood of response. 5 Therefore, the ability of DLT to induce complete durable response in relapsed AML may possibly be enhanced by early therapeutic intervention before the onset of hematologic relapse.
The major toxicities of the treatment are secondary to graft-versus-host disease (GVHD) and marrow aplasia. These complications have been the major causes of treatCorrespondence: Dr H Ogawa, Department of Medicine III, Osaka University Medical School, Department of Medicine III, 2-2, Yamada-Oka, Suita City, Osaka 565 Japan Received 11 July 1997; accepted 28 October 1997 ment-related mortality.
1 Early treatment may reduce the incidence of GVHD and marrow aplasia. 5 Recently we reported that WT1 expression levels provide a new marker for leukemic blast cells regardless of the type of leukemia and thus that minimal residual disease (MRD) of leukemia can be quantitatively measured by the quantitation of WT1 expression levels (WT1 assay).
6 WT1 asssay can detect frequencies of leukemic cells in bone marrow (BM) and peripheral blood (PB) as low as 10 −3 and 10
, respectively. Therefore, the WT1 assay is very useful for the diagnosis of molecular relapse of leukemia.
We present here a case of relapsed AML after BMT which was effectively treated with DLT at molecular relapse, diagnosed by WT1 assay and maintained in complete remission (CR) for more than 21 months after DLT.
Case report
A 47-year-old female was diagnosed as having AML with trilineage dysplasia in February 1993. She was treated successfully with daunorubicin-based combination chemotherapy, and received allogeneic bone marrow transplantation (BMT) from her HLA-identical brother in first CR in May 1994. The conditioning regimen included CY/TBI. GVHD prophylaxis was provided by a combination of cyclosporin A and a short course of methotrexate. Hematopoietic reconstitution was rapid with an absolute neutrophil count Ͼ0.5 × 10 9 /l on day 15 and a platelet count Ͼ50 × 10 9 /l on day 17. Cytogenetic analysis of BM sample on day 27 showed 100% donor type, 46(X,Y). She developed neither GVHD nor severe complications following BMT. Cyclosporin A was tapered off on day 227. We have previously reported that WT1 expression levels in PB or BM cells of leukemia patients reflect MRD and thus that the quantitation of WT1 expression levels allows us to monitor MRD. 6, 7 WT1 gene expression level in BM examined on day 104 was 1.9 × 10 −5 (the WT1 expression level in K562 cells was defined as 1.0; normal range, Ͻ1.0 × 10
−3
). Thereafter, WT1 gene expression levels in BM and PB gradually increased to 1.1 × 10 −3 and 3.2 × 10
on day 276 and 5.9 × 10 −3 and 2.4 × 10 −3 on day 367, respectively. However, cytogenetic analysis of a BM sam-ple on day 367 still showed 100% donor type, 46(X,Y). Since the increase in WT1 expression levels over 10 −2 in BM or 10 −3 in PB predicts certain clinical relapse in the near future, 7 we diagnosed this patient as having molecular relapse on day 367. In this situation we reasoned that DLT was the best available treatment for this patient. Therefore, viable buffy coat cells were harvested from her original marrow donor on 3 consecutive days using a CS3000 blood cell separator (Baxter, Deerfield, IL, USA). After each collection, apheresis products were freshly administered to the patient without GVHD prophylaxis. The total dose of donor CD3
+ cells was 2.1 × 10 8 /kg. The BM aspirate on the first day of DLT included only 2-3% myeloblasts, confirming that the patient was still in CR. Fluorescence in situ hybridization (FISH) analysis showed XY and XX signals in 98.0% and 1.8% of PB, respectively, indicating that the majority of PB cells were derived from donor hematopoietic progenitor cells. Since leukemic blast cells increased to 5 to 10% in BM after DLT, we administered interferon-␣ daily for 18 days and afterwards twice a week for 1 month. Leukemic blast cells reached a maximum (50%) 29 days after DLT, but thereafter rapidly decreased and became undetectable 39 days after DLT (Figure 1 ). The patient showed no evidence of GVHD or other complications. It is worth noting that the patient did not manifest marrow aplasia, which is a common complication of DLT. WT1 expression levels rapidly decreased from 29 days after DLT and returned to normal range 60 days after DLT. The patient is still in CR with a normal range of WT1 expression levels more than 21 months after DLT.
Materials and methods

Sample preparation and quantitation of WT1 mRNA
To prepare mononuclear cells from the patient, heparinized PB cells or BM aspirates were mixed with equal volumes of phosphate-buffered saline (PBS) and centrifuged on FicollIsopaque solution (Pharmacia, Uppsala, Sweden). Mononuclear cells were collected by centrifugation and the pellet was washed twice with PBS to remove platelets. Cells (1 × 10 6 to 1 × 10 7 ) were then dissolved in 0.5 ml of solution D (4 mol/l guanidine thiocyanate, 25 mmol/l sodium citrate, pH 7.0, 0.5% sarcosyl, 0.1 mol/l 2-mercaptoethanol) and stored at −80°C until use.
Quantitative reverse-transcriptase-polymerase chain reaction (RT-PCR) was performed as previously described.
Discussion
We reported here a case of relapsed AML after BMT, in which durable CR was achieved, without GVHD and bone marrow aplasia which are common complications of DLT, by early treatment with DLT at molecular relapse that was diagnosed by monitoring of MRD by WT1 assay. This is the first case indicating that an early treatment with DLT at molecular relapse is instrumental in AML to achieve durable CR.
DLT is effective, with a CR rate of approximately 80%, for relapsed CML patients after BMT. 1 It was much less effective for relapsed AML patients post-BMT. 1, 3, 4 Only one quarter of AML patients who were treated with DLT achieved CR of short duration. 1 The cause of the difference in efficacy of DLT between CML and AML remains undetermined. However, CML might have tumor-specific antigenicity (eg for bcr/abl oncoprotein) stronger than AML. Immunotherapy is generally more effective for patients who bear a low tumor burden. 8 In fact, it has been suggested that the size of tumor burden allows us to predict response to DLT for patients with CML. 5 Therefore, DLT at early stage of relapse may be effective for the improvement of the efficacy of DLT for patients with AML. In the present case, DLT was very effective probably because it was done at molecular relapse of AML. Thus, early diagnosis of relapse by WT1 assay and the subsequent early application of DLT should be recommended for successful DLT for patients with AML. It remained undetermined, however, how early DLT should be performed for patients with relapsing AML. Further study to address this issue is needed.
Major toxicities of DLT are marrow aplasia and GVHD that occur in approximately 50% and 90% of responders, respectively. 2, 9, 10 Marrow aplasia is best explained by a direct cytotoxic effect of the transfused lymphocytes on hematopoietic cells of the host, as seen in transfusion-associated GVHD.
11 Therefore, marrow aplasia may occur more often in responding patients whose bone marrow is almost completely occupied with leukemic cells, thus having few donor hematopoietic progenitor cells. Thus, marrow aplasia may be avoidable by the application of DLT at an early stage of molecular relapse, when the tumor burden is small and donor cells are well represented without complete occupation of bone marrow by leukemic cells. Futhermore, early application of DLT could reduce the dose of donor leukocytes required for effective DLT, resulting in the reduction in incidence of GVHD. 12 Monitoring of MRD is essential for early application of DLT at molecular relapse. Monitoring of MRD by WT1 assay is applicable to almost all leukemias regardless of presence or absence of tumor-specific DNA markers 6 and convenient for diagnosis of molecular relapse and assessing the efficacy of treatments including DLT. Actually, after falling in parallel with the decrease of leukemic blasts after DLT, WT1 levels continued to decrease even after morphological disappearance of leukemic blasts and normalized 1 month after clinical remission. This normalization of WT1 levels after DLT strongly suggests that CR is durable and that additional treatments with DLT are not necessary. Therefore, all patients who are treated with BMT should be followed for MRD by WT1 assay. In leukemia patients post-BMT, DLT should be done as soon as WT1 expression increases to 10 −2 levels in BM samples or 10 −3 levels in PB samples, which suggests that clinical relapse is imminent.
